About FDA

Brian Erkkila, Ph.D. and Susan M. Chemerynski, ScD, M.P.H.

 

 Brian E. Erkkila

Susan M. Chemerynski

Brian E. Erkkila, Ph.D
Division of Nonclinical Science (DNCS)
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993

Background:
BA – Neuroscience
Johns Hopkins University

PhD – Neurobiology
University of Alabama – Birmingham

4 years with the US FDA Center for Tobacco Products
 

 

Susan M. Chemerynski, ScD, MPH
Division of Nonclinical Science (DNCS)
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993

Background:
BA – Public Health
Johns Hopkins University

MPH- Environmental Health Sciences
Yale University School of Medicine

ScD – Environmental Science and Risk Management
Harvard School of Public Health

2 years with the US FDA Center for Tobacco Products
 

Research Interests

The Division of Nonclinical Science (DNCS) supports the Center for Tobacco Products Office of Science by providing sound scientific evidence for implementation of the Family Smoking Prevention and Tobacco Control Act. One way DNCS does this is through reviewing applications for substantial equivalent tobacco products, premarket tobacco products, or modified risk tobacco products. Additionally DNCS plans, evaluates and supports a number of research projects aimed at informing our regulatory decision making. Lastly, DNCS provides scientific support for the development of guidance and regulations aimed at protecting the American public from the burden of tobacco related disease.

Proposed Research Project for FDA Commissioner's Fellow

Our goal in DNCS is to use the most current and reliable scientific data to inform our regulatory decision making. In order to do so, it is imperative that we remain abreast of cutting edge research in the fields of toxicology, pharmacology, and risk assessment. Thus, based on the need within the Center, projects may include:

• Interpreting toxicological data from multiple data streams to better elucidate the mechanism of tobacco related disease;
• Developing computational models to evaluate risks to public health from tobacco products;
• Evaluation and refinement of the toxicological and statistical methods and data used to provide dose-response relationships in a model;
• Using modeling-specific techniques to evaluate the range of uncertainty and variability associated with tobacco-related risk.

Applicant Requirements

• Ph.D. or Pharm.D. and research training in pharmacology and/or toxicology is required.
• Knowledge of physiologically-based pharmacokinetic/pharmacodynamic models and dose-response analysis is required.
• Knowledge of risk assessment or risk analysis is preferred.

Selected Recent Publications:

Tricoire, L., Pelkey, K.A., Erkkila, B.E., Jeffries, B.W., Yuan, X., Mcbain, C.J. (2013).Dual embryonic origin of functionally distinct hippocampal O-LM cells revealed by differential 5-HT3AR expression. Nature Neuroscience 16, 1589-1607.

Tricoire, L., Pelkey, K.A., Erkkila, B.E., Jeffries, B.W., Yuan, X., Mcbain, C.J. (2011). A blueprint for the spatiotemporal origins of mouse hippocampal internuron diversity. The Journal of Neuroscience. 31 (30), 10948-70.

B. E. Erkkila, A. V. Sedelnikova, & D. S. Weiss. (2008). Stoichiometric pore mutations of the GABAAR reveal a pattern of hydrogen bonding with picrotoxin Biophysical Journal, 94(11), 4299-4236

Lewis A.S., Sax S.N., Chemerynski S.M., Campleman S.L. Non-Chemical Stressors and Cumulative Risk Assessment: An Overview of Current Initiatives and Potential Air Pollutant Interactions. Int. J. Environ. Res. Public Health. 2011; 8(6):2020-2073.

Chemerynski S.,, Julien, R, Perry, MJ, Smith, TJ, Levy, JI. Modeling exposures to organophosphates and pyrethroids for children living in an urban low-income environment. Environ. Res. 2013. Jul;124:13-22.

Chemerynski S.,, Smith, TJ, Perry MJ, Levy JI. Using physiologically-based pharmacokinetic models to incorporate chemical and non-chemical stressors into cumulative risk assessment: A case study of pesticide exposures. Int. J. Environ. Res. Public Health, Special issue “Cumulative health risk assessment.” 2012; 9(5):1971-83.
 

Page Last Updated: 03/30/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English